Skip to main content
Enwei Pharmaceutical Co., Ltd. logo

Enwei Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 301331 ISIN · CNE100005LC7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2022-09-01 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301331

About Enwei Pharmaceutical Co., Ltd.

https://www.enwei.com.cn

Enwei Pharmaceutical Co., Ltd. focuses on the research, development, and manufacturing of medicinal products, specializing in Chinese patent medicines and chemical drugs. The company is primarily known for its gynecological health solutions, most notably the Jie Er Yin brand. Its diverse product range covers therapeutic categories such as pediatrics, dermatology, and respiratory care. By combining traditional Chinese medicine with modern pharmacological standards, the company produces various dosage forms including lotions, capsules, and granules. The organization emphasizes clinical efficacy and quality management, targeting a wide range of healthcare needs through ongoing innovation in formulation and drug delivery systems.

Recent filings

Filing Released Lang Actions
财务数据及审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an audit report for the years 2019, 2020, and 2021 for 恩威医药股份有限公司. It contains detailed audit opinions, audit basis, key audit matters, and extensive financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. The presence of detailed auditor's responsibilities, management responsibilities, and audit procedures confirms this is a standalone audit report rather than a full annual report or a brief announcement. The document length is substantial (15,000 characters), and it includes comprehensive financial data and audit commentary. Therefore, it fits the definition of an Audit Report / Information (AR). FY 2021
2022-09-01 Chinese
监事对招股说明书的确认意见
Regulatory Filings Classification · 90% confidence The document text is extremely short (130 characters) and contains only references to omitted pictures with no substantive text or financial data. There is no indication of any report, announcement, or regulatory filing content. Given the lack of content, the document does not fit any specific filing category and defaults to the fallback category for miscellaneous filings.
2022-09-01 Chinese
公司章程(草案)
Regulatory Filings
2022-09-01 Chinese
董事会和股东大会决议
Regulatory Filings
2022-09-01 Chinese
恩威医药股份有限公司首次公开发行股票并在创业板上市网上路演公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of shares by 恩威医药股份有限公司 and the related online roadshow event. It includes details about the share issuance, regulatory approvals, and the schedule for the online roadshow. The document does not contain financial statements or detailed financial analysis but serves as an update on the capital raising process and investor engagement activities. This fits the definition of a Capital/Financing Update (CAP) as it relates to fundraising and capital structure changes.
2022-09-01 Chinese
律师工作报告
Regulatory Filings Classification · 95% confidence The document is a detailed legal work report issued by a law firm (北京市金杜律师事务所) regarding the initial public offering (IPO) and listing of 恩威医药股份有限公司 on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive legal due diligence, verification of company qualifications, approvals, authorizations, and compliance with relevant laws and regulations. The document references the issuance and listing process, legal opinions, and compliance with securities laws and stock exchange rules. It is not a financial report, earnings release, or management discussion but a legal report related to the IPO process. This type of document corresponds to a legal or regulatory filing related to the IPO process but is not a proxy statement, voting results, or a general regulatory announcement. Given the nature of the document as a comprehensive legal work report for the IPO, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not neatly fit into other categories, especially legal and compliance reports related to securities issuance.
2022-09-01 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.